| Source: |
| Type: |
| PD-L1 is a protein that plays a crucial role in the regulation of the immune system.
PD-L1 helps to prevent the immune system from attacking healthy cells by binding to its receptor, PD-1, on immune cells. However, some cancer cells can exploit this mechanism by expressing high levels of PD-L1, which can help them evade immune detection. PD-L1 has become a key target for cancer immunotherapy, particularly in the development of checkpoint inhibitors. PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype. PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers. |
| Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for 80–90% of kidney neoplasms. The activation of the mTOR pathway has been found in RCC and is correlated with high grade and poor prognostic patient features (41,42). |
| - | in-vitro, | RCC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:24 Cells:% prod#:% Target#:243 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid